Published in Lancet Oncol on January 16, 2013
Mutational landscape and significance across 12 major cancer types. Nature (2013) 14.91
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet (2014) 5.74
Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet (2013) 4.61
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res (2013) 2.26
Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology (2013) 2.21
Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol (2014) 1.65
An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC). BMC Genomics (2016) 1.46
Renal cell carcinoma. BMJ (2014) 1.45
Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer (2013) 1.36
Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Res (2013) 1.31
A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res (2013) 1.30
Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. Eur Urol (2014) 1.21
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis (2014) 1.17
The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Med (2014) 1.16
A clear picture of renal cell carcinoma. Nat Genet (2013) 1.15
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep (2016) 1.15
Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. J Urol (2015) 1.12
Adjuvant therapy for renal cell carcinoma: past, present, and future. Oncologist (2014) 1.11
PBRM1 and BAP1 as novel targets for renal cell carcinoma. Cancer J (2013) 1.07
Cooperation and antagonism among cancer genes: the renal cancer paradigm. Cancer Res (2013) 1.04
Renal cell carcinoma: molecular biology and targeted therapy. Curr Opin Oncol (2014) 1.01
MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther (2013) 1.01
Mutations of epigenetic regulatory genes are common in thymic carcinomas. Sci Rep (2014) 1.00
Driver mutations of cancer epigenomes. Protein Cell (2014) 0.98
Epigenomic regulation of oncogenesis by chromatin remodeling. Oncogene (2016) 0.97
Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis. Proc Natl Acad Sci U S A (2014) 0.97
Racial difference in histologic subtype of renal cell carcinoma. Cancer Med (2013) 0.96
Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet (2015) 0.94
Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas-Renal Cell Carcinoma (TCGA-RCC) Imaging Research Group. Abdom Imaging (2015) 0.87
Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma. Front Oncol (2014) 0.85
Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc Natl Acad Sci U S A (2016) 0.85
Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma. Oncotarget (2016) 0.85
The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer. Cancer Genet (2015) 0.85
High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes. PLoS One (2015) 0.85
Beyond Mutations: Additional Mechanisms and Implications of SWI/SNF Complex Inactivation. Front Oncol (2015) 0.85
Molecular targets on the horizon for kidney and urothelial cancer. Nat Rev Clin Oncol (2013) 0.82
ROTS: reproducible RNA-seq biomarker detector-prognostic markers for clear cell renal cell cancer. Nucleic Acids Res (2015) 0.82
Impact of recurrent copy number alterations and cancer gene mutations on the predictive accuracy of prognostic models in clear cell renal cell carcinoma. J Urol (2014) 0.82
Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis (2014) 0.82
Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response. Cancer Med (2014) 0.81
Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. Mod Pathol (2015) 0.81
Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors. Onco Targets Ther (2013) 0.81
The epigenetic landscape of renal cancer. Nat Rev Nephrol (2016) 0.81
TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. Mod Pathol (2015) 0.80
Precision medicine from the renal cancer genome. Nat Rev Nephrol (2016) 0.80
The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma. J Am Soc Nephrol (2016) 0.80
Expression of IL-4 and IL-13 predicts recurrence and survival in localized clear-cell renal cell carcinoma. Int J Clin Exp Pathol (2015) 0.80
Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma. Urol Oncol (2014) 0.80
Tumour and patient factors in renal cell carcinoma-towards personalized therapy. Nat Rev Urol (2015) 0.78
Renal-cell carcinoma: a step closer to a new classification. Lancet Oncol (2013) 0.77
Challenges in RCC Imaging: Renal Insufficiency, Post-Operative Surveillance, and the Role of Radiomics. Kidney Cancer J (2015) 0.77
Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance. BMC Cancer (2016) 0.77
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. Oncotarget (2015) 0.77
Medical treatment of renal cancer: new horizons. Br J Cancer (2016) 0.76
Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact. Curr Opin Urol (2016) 0.75
ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics. Ann Transl Med (2016) 0.75
Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms. Biomed Res Int (2015) 0.75
Clear Cell Renal Cell Carcinoma: Associations Between CT Features and Patient Survival. AJR Am J Roentgenol (2016) 0.75
BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor. BMC Urol (2017) 0.75
The epigenetic landscape of clear-cell renal cell carcinoma. J Kidney Cancer VHL (2015) 0.75
Imaging-genomic pipeline for identifying gene mutations using three-dimensional intra-tumor heterogeneity features. J Med Imaging (Bellingham) (2015) 0.75
Discovering Biomarkers within the Genomic Landscape of Renal Cell Carcinoma. J Kidney (2016) 0.75
Down-regulation of C12orf59 is associated with a poor prognosis and VHL mutations in renal cell carcinoma. Oncotarget (2016) 0.75
Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues. Oncotarget (2016) 0.75
Subtyping of renal cortical neoplasms in fine needle aspiration biopsies using a decision tree based on genomic alterations detected by fluorescence in situ hybridization. BJU Int (2014) 0.75
BRCA1-associated protein 1 deficiency in lung adenocarcinoma predicts poor outcome and increased tumor invasion. BMC Cancer (2016) 0.75
[Novel biomarkers in renal cell carcinoma : Identification and functional characterization]. Pathologe (2015) 0.75
Targeted therapies for renal cell carcinoma. Nat Rev Nephrol (2017) 0.75
Modeling Renal Cell Carcinoma in mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade. Cancer Discov (2017) 0.75
Somatic BRCA1-associated protein 1 (BAP1) loss is an early and rare event in esophageal adenocarcinoma. Mol Clin Oncol (2017) 0.75
Downregulation of Na(+)/Ca(2+) Exchanger Isoform 1 Protects Isolated Hearts by Sevoflurane Postconditioning but Not by Delayed Remote Ischemic Preconditioning in Rats. Chin Med J (Engl) (2017) 0.75
Prognostic role of BAP1 in pT1 clear cell carcinoma in partial nephrectomy specimens. Virchows Arch (2017) 0.75
PBRM1 loss is a late event during the development of cholangiocarcinoma. Histopathology (2017) 0.75
Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. Eur Urol Focus (2016) 0.75
Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Urol Oncol (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol (1982) 8.47
Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol (1999) 8.46
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Frequent mutation of BAP1 in metastasizing uveal melanomas. Science (2010) 7.47
Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev (2000) 5.53
BAP1 loss defines a new class of renal cell carcinoma. Nat Genet (2012) 4.97
HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell (2002) 4.82
Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol (2001) 4.22
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer (2010) 3.78
Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet (2011) 3.66
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
A postoperative prognostic nomogram for renal cell carcinoma. J Urol (2001) 3.01
Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer (2007) 2.38
Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol (2007) 2.09
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol (2005) 2.05
Chromatin-mediated regulation of nucleolar structure and RNA Pol I localization by TOR. EMBO J (2003) 1.88
A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med (2012) 1.84
O-GlcNAc transferase/host cell factor C1 complex regulates gluconeogenesis by modulating PGC-1α stability. Cell Metab (2012) 1.46
Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer (2005) 1.43
VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. Am J Surg Pathol (2010) 1.19
Pathologic features of renal cortical tumors. Urol Clin North Am (2008) 1.13
Grading of clear cell renal cell carcinoma should be based on nucleolar prominence. Am J Surg Pathol (2011) 0.91